These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10909192)

  • 21. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.
    Romines KR; Watenpaugh KD; Tomich PK; Howe WJ; Morris JK; Lovasz KD; Mulichak AM; Finzel BC; Lynn JC; Horng MM
    J Med Chem; 1995 May; 38(11):1884-91. PubMed ID: 7783120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.
    Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A
    Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity.
    Kågedahl M; Swaan PW; Redemann CT; Tang M; Craik CS; Szoka FC; Oie S
    Pharm Res; 1997 Feb; 14(2):176-80. PubMed ID: 9090705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
    Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
    J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM; Andrews W; Furfine E; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5689-92. PubMed ID: 15482949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of a macromolecular inhibitor of HIV-1 protease.
    Dauber DS; McPhee F; Unal A; Craik CS
    Adv Exp Med Biol; 1998; 436():65-70. PubMed ID: 9561201
    [No Abstract]   [Full Text] [Related]  

  • 29. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
    Bouzide A; Sauvé G; Yelle J
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1509-13. PubMed ID: 15713418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
    Sherrill RG; Furfine ES; Hazen RJ; Miller JF; Reynolds DJ; Sammond DM; Spaltenstein A; Wheelan P; Wright LL
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3560-4. PubMed ID: 15975788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.
    Rutenber EE; De Voss JJ; Hoffman L; Stroud RM; Lee KH; Alvarez J; McPhee F; Craik C; Ortiz de Montellano PR
    Bioorg Med Chem; 1997 Jul; 5(7):1311-20. PubMed ID: 9377091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
    Duffy JL; Kevin NJ; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2423-6. PubMed ID: 12161148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease.
    Viswanadhan VN; Reddy MR; Wlodawer A; Varney MD; Weinstein JN
    J Med Chem; 1996 Feb; 39(3):705-12. PubMed ID: 8576913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
    Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and activity of N-benzyl pseudopeptides HIV protease inhibitors.
    Marastoni M; Bazzaro M; Bortolotti F; Tomatis R
    Bioorg Med Chem; 2003 May; 11(11):2477-83. PubMed ID: 12735995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.